Mirikizumab for treating moderately to severely active ulcerative colitis

2.1 Mirikizumab (Omvoh, Eli Lilly) is indicated for: 'the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.'

2.2 The dosage schedule is available in the summary of product characteristics for mirikizumab.

2.3 The list price is £2,056.56 (excluding VAT; emc med data browser accessed August 2023) per:

2.4 The company has a commercial arrangement. This makes mirikizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.